International Journal of Nephrology combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients,” Journal of the American Society of Nephrology, vol. 15, no. 8, pp. 2186–2194, 2004. [16] P. K. Li, K. M. Chow, T. Y. Wong, C. B. Leung, and C. C. Szeto, “Eﬀects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis: a randomized, controlled study,” Annals of Internal Medicine, vol. 139, no. 2, pp. 105–112, 2003. [17] N. Aslam, J. Bernardini, L. Fried, R. Burr, and B. Piraino, “Comparison of infectious complications between incident hemodialysis and peritoneal dialysis patients,” Clinical Journal of the American Society of Nephrology, vol. 1, no. 6, pp. 1226– 1233, 2006. [18] N. R. Powe, B. Jaar, S. L. Furth, J. Hermann, and W. Briggs, “Septicemia in dialysis patients: incidence, risk factors, and prognosis,” Kidney International, vol. 55, no. 3, pp. 1081–1090, 1999. [19] F. H. Bender, J. Bernardini, and B. Piraino, “Prevention of infectious complications in peritoneal dialysis: best demon- strated practices,” Kidney International Supplements, vol. 70, no. 103, pp. S44–S54, 2006. [20] J. B. Wasserfallen, M. Moinat, G. Halabi et al., “Satisfaction of patients on chronic haemodialysis and peritoneal dialysis,” Swiss Medical Weekly, vol. 136, no. 13-14, pp. 210–217, 2006. [21] H. R. Rubin, N. E. Fink, L. C. Plantinga, J. H. Sadler, A. S. Kliger, and N. R. Powe, “Patient ratings of dialysis care with peritoneal dialysis vs hemodialysis,” Journal of the American Medical Association, vol. 291, no. 6, pp. 697–703, 2004. [22] R. Vanholder, P. Heering, A. Van Loo et al., “Reduced incidence of acute renal graft failure in patients treated with peritoneal dialysis compared with hemodialysis,” American Journal of Kidney Diseases, vol. 33, no. 5, pp. 934–940, 1999. [23] R. Palomar, P. Morales, E. Rodrigo et al., “Venous graft throm- bosis in patients on peritoneal dialysis before transplantation,” Transplantation Proceedings, vol. 39, no. 7, pp. 2128–2130, 2007. [24] Y. Chalem, J. P. Ryckelynck, P. Tuppin, C. Verger, S. Chauve´, and D. Glotz, “Access to, and outcome of, renal transplantation according to treatment modality of end-stage renal disease in France,” Kidney International, vol. 67, no. 6, pp. 2448–2453, 2005. [25] A. S. Goldfarb-Rumyantzev, J. F. Hurdle, J. D. Scandling, B. C. Baird, and A. K. Cheung, “The role of pretransplantation renal replacement therapy modality in kidney allograft and recipient survival,” American Journal of Kidney Diseases, vol. 46, no. 3, pp. 537–549, 2005. [26] Y. C. Shih, A. Guo, P. M. Just, and S. Mujais, “Impact of initial dialysis modality and modality switches on Medicare expenditures of end-stage renal disease patients,” Kidney International, vol. 68, no. 1, pp. 319–329, 2005. [27] A. Berger, J. Edelsberg, G. W. Inglese, S. K. Bhattacharyya, and G. Oster, “Cost comparison of peritoneal dialysis versus hemodialysis in end-stage renal disease,” American Journal of Managed Care, vol. 15, no. 8, pp. 509–518, 2009. [28] “Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes. Canada-USA (CANUSA) Peritoneal Dialysis Study Group,” Journal of the American Society of Nephrology, vol. 7, no. 2, pp. 198–207, 1996. [29] R. Paniagua, D. Amato, E. Vonesh et al., “Eﬀects of increased peritoneal clearances on mortality rates in peritoneal dialysis: 5 ADEMEX, a prospective, randomized, controlled trial,” Jour- nal of the American Society of Nephrology, vol. 13, no. 5, pp. 1307–1320, 2002. [30] W. K. Lo, Y. W. Ho, C. S. Li et al., “Eﬀect of Kt/V on survival and clinical outcome in CAPD patients in a randomized prospective study,” Kidney International, vol. 64, no. 2, pp. 649–656, 2003. [31] P. J. Margetts and D. N. Churchill, “Acquired ultraﬁltration dysfunction in peritoneal dialysis patients,” Journal of the American Society of Nephrology, vol. 13, no. 11, pp. 2787–2794, 2002. [32] M. L. Lambie, B. John, L. Mushahar, C. Huckvale, and S. J. Davies, “The peritoneal osmotic conductance is low well before the diagnosis of encapsulating peritoneal sclerosis is made,” Kidney International, vol. 78, no. 6, pp. 611–618, 2010. [33] K. J. Jager, M. P. Merkus, F. W. Dekker et al., “Mortality and technique failure in patients starting chronic peritoneal dialysis: results of the netherlands cooperative study on the adequacy of dialysis,” Kidney International, vol. 55, no. 4, pp. 1476–1485, 1999. [34] Y. Kawaguchi, T. Hasegawa, M. Nakayama, H. Kubo, and T. Shigematu, “Issues aﬀecting the longevity of the continuous peritoneal dialysis therapy,” Kidney International, vol. 51, no. 62, pp. S105–S107, 1997. [35] R. Kuriyama, A. Tranaeus, and T. Ikegami, “Icodextrin reduces mortality and the drop-out rate in japanese peritoneal dialysis patients,” Advances in Peritoneal Dialysis, vol. 22, pp. 108–110, 2006. [36] H. Y. Choi, D. K. Kim, T. H. Lee et al., “The clinical usefulness of peritoneal dialysis ﬂuids with neural pH and low glucose degradation product concentration: an open randomized prospective trial,” Peritoneal Dialysis International, vol. 28, no. 2, pp. 174–182, 2008. [37] B. Rippe, O. Simonsen, O. Heimbu¨rger et al., “Long-term clinical eﬀects of a peritoneal dialysis ﬂuid with less glucose degradation products,” Kidney International, vol. 59, no. 1, pp. 348–357, 2001. [38] J. H. Crabtree and R. J. Burchette, “Eﬀective use of laparoscopy for long-term peritoneal dialysis access,” American Journal of Surgery, vol. 198, no. 1, pp. 135–141, 2009. [39] T. Golper, “Patient education: can it maximize the success of therapy?” Nephrology Dialysis Transplantation, vol. 16, supplement 7, pp. 20–24, 2001.